Simulations Plus

Hello to all our work-from-home researchers and those who are bravely returning to the lab.

STARTING NEXT WEEK! Featured Seminar Series: GastroPlus® Additional Dosage Routes

We have all enjoyed the new atmosphere of children, dogs and technical difficulties with our computers. Hopefully, we will return to a less worrisome world shortly.

StrategiesPlus™ COVID-19 ACT Program to speed consulting assistance to any organization involved in coronavirus research.

Since last month’s newsletter, the world has become Coronavirus conscious.

Throughout the drug discovery process, companies need to eliminate poor drug candidates early to avoid costly studies and dead ends.

It is still winter and cold here in New England; however the workshop and meeting schedule is heating up!

In trying to share the excitement that is building in the SimsPlus development team for the new GPX™ platform… I can only think of the signature Frank Sinatra song “The Best is yet to Come”

Thank you to everyone who joined us for the Simulations Plus, Inc. Annual Forum at American Association of Pharmaceutical Scientists (AAPS) Pharmsci360 in San Antonio, TX.

Taking fit-for-purpose (F4P) models to the next level – Collaboration between scientists and software designers

Walt Woltosz, chairman of Simulations Plus Inc., commented on the passing of world-famous astrophysicist, Professor Sir Stephen Hawking...
"Stephen Hawking was a remarkable man and a global scientific leader. But he was also charming and witty, with a nice sense of humor. He would "dance" in his electric wheelchair at festive events, spinning in circles and dazzling all who watched. He made his place in history, along with Newton, Einstein, Bohr, and so many others. He will be missed."

Envisioned by Cognigen Corporation, a Simulations Plus (Nasdaq:SLP) company, in 2003, the Pharma of the FutureSM (PoF) program was conceived as a research and training initiative to design and implement the workflows and computer systems required to support modeling and simulation (M&S) activities.

Prior to 1978, PK data was obtained from drugs that were tested on healthy young volunteers (typically medical students).